Phase 2, Open-Label, Clinical Trial of Miravirsen Sodium in Combination With Telaprevir and Ribavirin in Null Responders to Pegylated-Interferon Alpha Plus Ribavirin Subjects With Chronic Hepatitis C Virus Genotype 1 Infection
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 21 Nov 2014
At a glance
- Drugs Miravirsen (Primary) ; Ribavirin; Telaprevir
- Indications Hepatitis C
- Focus Therapeutic Use
- Sponsors Santaris Pharma
- 17 Nov 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 26 Jun 2013 New trial record
- 01 Jun 2013 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.